Connection

Adolfo García-Sastre to Humans

This is a "connection" page, showing publications Adolfo García-Sastre has written about Humans.
Connection Strength

0.147
  1. Immunological imprinting of the antibody response in COVID-19 patients. Nat Commun. 2021 06 18; 12(1):3781.
    View in: PubMed
    Score: 0.008
  2. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021 02 26; 371(6532):926-931.
    View in: PubMed
    Score: 0.007
  3. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci U S A. 2020 11 10; 117(45):28344-28354.
    View in: PubMed
    Score: 0.007
  4. An Immunocompetent Mouse Model of Zika Virus Infection. Cell Host Microbe. 2018 05 09; 23(5):672-685.e6.
    View in: PubMed
    Score: 0.006
  5. Specific Mutations in the PB2 Protein of Influenza A Virus Compensate for the Lack of Efficient Interferon Antagonism of the NS1 Protein of Bat Influenza A-Like Viruses. J Virol. 2018 04 01; 92(7).
    View in: PubMed
    Score: 0.006
  6. Ten Strategies of Interferon Evasion by Viruses. Cell Host Microbe. 2017 Aug 09; 22(2):176-184.
    View in: PubMed
    Score: 0.006
  7. Antagonism of type I interferon by flaviviruses. Biochem Biophys Res Commun. 2017 10 28; 492(4):587-596.
    View in: PubMed
    Score: 0.006
  8. Inactivated influenza virus vaccines: the future of TIV and QIV. Curr Opin Virol. 2017 04; 23:102-106.
    View in: PubMed
    Score: 0.006
  9. 2 methylate or not 2 methylate: viral evasion of the type I interferon response. Nat Immunol. 2011 Feb; 12(2):114-5.
    View in: PubMed
    Score: 0.004
  10. A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners. Emerg Microbes Infect. 2021 Dec; 10(1):376-383.
    View in: PubMed
    Score: 0.002
  11. Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice. J Virol. 2021 08 10; 95(17):e0040221.
    View in: PubMed
    Score: 0.002
  12. Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity. Cell Rep Med. 2021 08 17; 2(8):100369.
    View in: PubMed
    Score: 0.002
  13. After the pandemic: perspectives on the future trajectory of COVID-19. Nature. 2021 08; 596(7873):495-504.
    View in: PubMed
    Score: 0.002
  14. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science. 2021 07 30; 373(6554):541-547.
    View in: PubMed
    Score: 0.002
  15. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. Sci Rep. 2021 06 10; 11(1):12310.
    View in: PubMed
    Score: 0.002
  16. Control of Innate Immune Activation by Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses. J Interferon Cytokine Res. 2021 06; 41(6):205-219.
    View in: PubMed
    Score: 0.002
  17. Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. Hum Pathol. 2021 08; 114:110-119.
    View in: PubMed
    Score: 0.002
  18. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Rep. 2021 05 18; 35(7):109133.
    View in: PubMed
    Score: 0.002
  19. Functional landscape of SARS-CoV-2 cellular restriction. Mol Cell. 2021 06 17; 81(12):2656-2668.e8.
    View in: PubMed
    Score: 0.002
  20. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol. 2021 08; 34(8):1456-1467.
    View in: PubMed
    Score: 0.002
  21. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell. 2021 05 13; 184(10):2618-2632.e17.
    View in: PubMed
    Score: 0.002
  22. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*. Angew Chem Int Ed Engl. 2021 04 19; 60(17):9467-9473.
    View in: PubMed
    Score: 0.002
  23. Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology. 2021 06; 160(7):2435-2450.e34.
    View in: PubMed
    Score: 0.002
  24. Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. Sci Adv. 2021 02; 7(6).
    View in: PubMed
    Score: 0.002
  25. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell Rep. 2021 01 12; 34(2):108628.
    View in: PubMed
    Score: 0.002
  26. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect. 2020 Dec; 9(1):2433-2445.
    View in: PubMed
    Score: 0.002
  27. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med. 2020 12 24; 383(26):2586-2588.
    View in: PubMed
    Score: 0.002
  28. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020 12 18; 370(6523):1473-1479.
    View in: PubMed
    Score: 0.002
  29. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020 12 04; 370(6521).
    View in: PubMed
    Score: 0.002
  30. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
    View in: PubMed
    Score: 0.002
  31. Animal models for COVID-19. Nature. 2020 10; 586(7830):509-515.
    View in: PubMed
    Score: 0.002
  32. Current Status of COVID-19 (Pre)Clinical Vaccine Development. Angew Chem Int Ed Engl. 2020 10 19; 59(43):18885-18897.
    View in: PubMed
    Score: 0.002
  33. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol. 2020 09; 58(1):e108.
    View in: PubMed
    Score: 0.002
  34. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020 10; 586(7827):113-119.
    View in: PubMed
    Score: 0.002
  35. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020 08 06; 182(3):685-712.e19.
    View in: PubMed
    Score: 0.002
  36. Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent. Kidney Int. 2020 09; 98(3):782.
    View in: PubMed
    Score: 0.002
  37. Introductions and early spread of SARS-CoV-2 in the New York City area. Science. 2020 07 17; 369(6501):297-301.
    View in: PubMed
    Score: 0.002
  38. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 07; 26(7):1033-1036.
    View in: PubMed
    Score: 0.002
  39. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 07; 583(7816):459-468.
    View in: PubMed
    Score: 0.002
  40. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Front Immunol. 2019; 10:756.
    View in: PubMed
    Score: 0.002
  41. Influenza Virus NS1 Protein-RNA Interactome Reveals Intron Targeting. J Virol. 2018 12 15; 92(24).
    View in: PubMed
    Score: 0.002
  42. Influenza virus infection causes global RNAPII termination defects. Nat Struct Mol Biol. 2018 09; 25(9):885-893.
    View in: PubMed
    Score: 0.002
  43. Transcription Elongation Can Affect Genome 3D Structure. Cell. 2018 09 06; 174(6):1522-1536.e22.
    View in: PubMed
    Score: 0.002
  44. Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine. Cold Spring Harb Perspect Biol. 2018 07 02; 10(7).
    View in: PubMed
    Score: 0.002
  45. Innate immune sensor LGP2 is cleaved by the Leader protease of foot-and-mouth disease virus. PLoS Pathog. 2018 06; 14(6):e1007135.
    View in: PubMed
    Score: 0.002
  46. Co-regulatory activity of hnRNP K and NS1-BP in influenza and human mRNA splicing. Nat Commun. 2018 06 19; 9(1):2407.
    View in: PubMed
    Score: 0.002
  47. Paramyxovirus V Proteins Interact with the RIG-I/TRIM25 Regulatory Complex and Inhibit RIG-I Signaling. J Virol. 2018 03 15; 92(6).
    View in: PubMed
    Score: 0.002
  48. SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses. Sci Rep. 2018 02 01; 8(1):2092.
    View in: PubMed
    Score: 0.002
  49. MERS-CoV 4b protein interferes with the NF-?B-dependent innate immune response during infection. PLoS Pathog. 2018 01; 14(1):e1006838.
    View in: PubMed
    Score: 0.002
  50. Pandemic H1N1 influenza A viruses suppress immunogenic RIPK3-driven dendritic cell death. Nat Commun. 2017 12 05; 8(1):1931.
    View in: PubMed
    Score: 0.001
  51. Single-cell analysis of early antiviral gene expression reveals a determinant of stochastic IFNB1 expression. Integr Biol (Camb). 2017 Nov 13; 9(11):857-867.
    View in: PubMed
    Score: 0.001
  52. Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication. PLoS Pathog. 2017 Sep; 13(9):e1006635.
    View in: PubMed
    Score: 0.001
  53. Human interactome of the influenza B virus NS1 protein. J Gen Virol. 2017 Sep; 98(9):2267-2273.
    View in: PubMed
    Score: 0.001
  54. Loss of Sendai virus C protein leads to accumulation of RIG-I immunostimulatory defective interfering RNA. J Gen Virol. 2017 Jun; 98(6):1282-1293.
    View in: PubMed
    Score: 0.001
  55. The RNA Exosome Syncs IAV-RNAPII Transcription to Promote Viral Ribogenesis and Infectivity. Cell. 2017 05 04; 169(4):679-692.e14.
    View in: PubMed
    Score: 0.001
  56. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017 04 14; 356(6334):175-180.
    View in: PubMed
    Score: 0.001
  57. Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. Nat Microbiol. 2017 Mar 27; 2:17037.
    View in: PubMed
    Score: 0.001
  58. Systems-based analysis of RIG-I-dependent signalling identifies KHSRP as an inhibitor of RIG-I receptor activation. Nat Microbiol. 2017 Mar 01; 2:17022.
    View in: PubMed
    Score: 0.001
  59. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat Immunol. 2017 04; 18(4):464-473.
    View in: PubMed
    Score: 0.001
  60. Influenza virus exploits tunneling nanotubes for cell-to-cell spread. Sci Rep. 2017 01 06; 7:40360.
    View in: PubMed
    Score: 0.001
  61. Influenza-infected neutrophils within the infected lungs act as antigen presenting cells for anti-viral CD8(+) T cells. PLoS One. 2012; 7(10):e46581.
    View in: PubMed
    Score: 0.001
  62. Suppression of the antiviral response by an influenza histone mimic. Nature. 2012 Mar 14; 483(7390):428-33.
    View in: PubMed
    Score: 0.001
  63. Structural basis for the removal of ubiquitin and interferon-stimulated gene 15 by a viral ovarian tumor domain-containing protease. Proc Natl Acad Sci U S A. 2011 Feb 08; 108(6):2222-7.
    View in: PubMed
    Score: 0.001
  64. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. J Gen Virol. 2009 Nov; 90(Pt 11):2686-2694.
    View in: PubMed
    Score: 0.001
  65. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol. 2006 Sep; 80(18):9192-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.